Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older at the time of signing the consent form
- People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer) that cannot be removed by surgery and is not suitable for — or has continued to grow after — local treatment procedures targeting the liver
- People whose liver is still functioning at a relatively healthy level, as measured by a standard liver scoring system called Child-Pugh class A (a score of 5 or 6)
- People who have not previously received any systemic (whole-body) drug treatment for their liver cancer — though people who relapsed more than 6 months after finishing post-surgery preventive treatment may still be considered eligible
- People who previously received a drug called lenvatinib alongside a local liver procedure called TACE may be considered eligible, provided the treating doctor confirmed they were suitable for TACE at the time (confirm with trial site)
- People who are planned to start a specific combination immunotherapy regimen — nivolumab plus ipilimumab — between 1 March 2026 and 28 February 2027, given as infusions on a set schedule
- People who provide written consent before starting that immunotherapy treatment
Who may not be able to join:
- People whose liver cancer has been identified as a specific rare subtype, including fibrolamellar, sarcomatoid, or mixed cholangiocarcinoma types
- People who have previously had a liver transplant
- People whose general physical health and ability to carry out daily activities is significantly limited, as measured by a standard scale called the ECOG performance status score of 3 or higher
- People with other serious health conditions that remain uncontrolled even with treatment
- People who have another advanced cancer that requires systemic (whole-body) treatment
- People who have previously received any immunotherapy treatment (treatments that work through the immune system)
- People who are already enrolled in another interventional clinical trial at the time of joining this study
- People considered unsuitable for the trial by the doctor running the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with grade ≥3 immune-mediated liver injury (IMLI); Time to onset of immune-mediated liver injury (IMLI); Time to resolution of immune-mediated liver injury (IMLI); Number of participants with immune-mediated liver injury (IMLI) who achieve resolution (recovered, recovering, or recovered with sequelae); Treatment prescribed to participants for immune-mediated liver injury (IMLI); Objective response rate (ORR); Best overall response (BOR); Disease control rate (DCR; Duration of nivolumab plus ipilimumab combination therapy; Number of nivolumab plus ipilimumab treatment cyc...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.